196 related articles for article (PubMed ID: 8363756)
1. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus.
Stahl-Hennig C; Voss G; Dittmer U; Coulibaly C; Petry H; Makoschey B; Cranage MP; Aubertin AM; Lüke W; Hunsmann G
AIDS; 1993 Jun; 7(6):787-95. PubMed ID: 8363756
[TBL] [Abstract][Full Text] [Related]
2. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.
Shacklett BL; Shaw KE; Adamson LA; Wilkens DT; Cox CA; Montefiori DC; Gardner MB; Sonigo P; Luciw PA
J Virol; 2002 Nov; 76(22):11365-78. PubMed ID: 12388697
[TBL] [Abstract][Full Text] [Related]
3. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
[TBL] [Abstract][Full Text] [Related]
4. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge.
Dittmer U; Stahl-Hennig C; Coulibaly C; Nisslein T; Lüke W; Fuchs D; Bodemer W; Petry H; Hunsmann G
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1307-15. PubMed ID: 7782761
[TBL] [Abstract][Full Text] [Related]
5. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.
Connor RI; Montefiori DC; Binley JM; Moore JP; Bonhoeffer S; Gettie A; Fenamore EA; Sheridan KE; Ho DD; Dailey PJ; Marx PA
J Virol; 1998 Sep; 72(9):7501-9. PubMed ID: 9696847
[TBL] [Abstract][Full Text] [Related]
6. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.
Schmitz JE; Johnson RP; McClure HM; Manson KH; Wyand MS; Kuroda MJ; Lifton MA; Khunkhun RS; McEvers KJ; Gillis J; Piatak M; Lifson JD; Grosschupff G; Racz P; Tenner-Racz K; Rieber EP; Kuus-Reichel K; Gelman RS; Letvin NL; Montefiori DC; Ruprecht RM; Desrosiers RC; Reimann KA
J Virol; 2005 Jul; 79(13):8131-41. PubMed ID: 15956558
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.
Petry H; Dittmer U; Stahl-Hennig C; Coulibaly C; Makoschey B; Fuchs D; Wachter H; Tolle T; Morys-Wortmann C; Kaup FJ
J Virol; 1995 Mar; 69(3):1564-74. PubMed ID: 7853490
[TBL] [Abstract][Full Text] [Related]
8. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.
de Vries P; Heeney JL; Boes J; Dings ME; Hulskotte EG; Dubbes R; Koornstra W; ten Haaft P; Akerblom L; Eriksson S
Vaccine; 1994 Nov; 12(15):1443-52. PubMed ID: 7887023
[TBL] [Abstract][Full Text] [Related]
9. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
[TBL] [Abstract][Full Text] [Related]
10. Specific and non-specific immunity and protection of macaques against SIV infection.
Le Grand R; Vogt G; Vaslin B; Roques P; Théodoro F; Aubertin AM; Dormont D
Vaccine; 1992; 10(12):873-9. PubMed ID: 1455913
[TBL] [Abstract][Full Text] [Related]
11. Passive immunization of rhesus macaques against SIV infection and disease.
Gardner M; Rosenthal A; Jennings M; Yee J; Antipa L; Robinson E
AIDS Res Hum Retroviruses; 1995 Jul; 11(7):843-54. PubMed ID: 7546912
[TBL] [Abstract][Full Text] [Related]
12. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
[TBL] [Abstract][Full Text] [Related]
13. SIV vaccine protection of rhesus monkeys.
Gardner MB; Carlson JR; Jennings M; Rosenthal A; Langlois A; Haynes B; Bolognesi D; Palker TJ
Biotechnol Ther; 1991; 2(1-2):9-19. PubMed ID: 1845125
[TBL] [Abstract][Full Text] [Related]
14. Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection.
Stahl-Hennig C; Voss G; Nick S; Petry H; Fuchs D; Wachter H; Coulibaly C; Lüke W; Hunsmann G
Virology; 1992 Feb; 186(2):588-96. PubMed ID: 1733103
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants.
Rud EW; Cranage M; Yon J; Quirk J; Ogilvie L; Cook N; Webster S; Dennis M; Clarke BE
J Gen Virol; 1994 Mar; 75 ( Pt 3)():529-43. PubMed ID: 8126450
[TBL] [Abstract][Full Text] [Related]
16. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo.
Luke W; Coulibaly C; Dittmer U; Voss G; Oesterle R; Makoschey B; Sauermann U; Jurkiewicz E; Stahl-Henning C; Petry H; Hunsmann G
Virology; 1996 Feb; 216(2):444-50. PubMed ID: 8607276
[TBL] [Abstract][Full Text] [Related]
17. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
Putkonen P; Nilsson C; Hild K; Benthin R; Cranage M; Aubertin AM; Biberfeld G
J Med Primatol; 1993; 22(2-3):100-3. PubMed ID: 8411101
[TBL] [Abstract][Full Text] [Related]
18. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130.
Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G
J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957
[TBL] [Abstract][Full Text] [Related]
19. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.
Chan WL; Rodgers A; Grief C; Almond N; Ellis S; Flanagan B; Silvera P; Bootman J; Stott J; Kent K
AIDS; 1995 Mar; 9(3):223-8. PubMed ID: 7755909
[TBL] [Abstract][Full Text] [Related]
20. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus.
Ahmad S; Lohman B; Marthas M; Giavedoni L; el-Amad Z; Haigwood NL; Scandella CJ; Gardner MB; Luciw PA; Yilma T
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):195-204. PubMed ID: 8198872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
